Natus Medical Inc (BABY) : Voce Capital Management reduced its stake in Natus Medical Inc by 13.35% during the most recent quarter end. The investment management company now holds a total of 124,166 shares of Natus Medical Inc which is valued at $5,090,806 after selling 19,126 shares in Natus Medical Inc , the firm said in a disclosure report filed with the SEC on Nov 14, 2016.Natus Medical Inc makes up approximately 6.16% of Voce Capital Management’s portfolio.
Other Hedge Funds, Including , Aqr Capital Management boosted its stake in BABY in the latest quarter, The investment management firm added 2,410 additional shares and now holds a total of 75,791 shares of Natus Medical Inc which is valued at $3,107,431.Comerica Bank boosted its stake in BABY in the latest quarter, The investment management firm added 158 additional shares and now holds a total of 33,488 shares of Natus Medical Inc which is valued at $1,324,450. Natus Medical Inc makes up approx 0.01% of Comerica Bank’s portfolio.Alliancebernstein reduced its stake in BABY by selling 470 shares or 0.89% in the most recent quarter. The Hedge Fund company now holds 52,596 shares of BABY which is valued at $2,080,172.Victory Capital Management Inc reduced its stake in BABY by selling 267 shares or 13.71% in the most recent quarter. The Hedge Fund company now holds 1,681 shares of BABY which is valued at $63,626.Great West Life Assurance Co Can boosted its stake in BABY in the latest quarter, The investment management firm added 752 additional shares and now holds a total of 44,494 shares of Natus Medical Inc which is valued at $1,750,839. Natus Medical Inc makes up approx 0.01% of Great West Life Assurance Co Can’s portfolio.
Natus Medical Inc opened for trading at $43.65 and hit $43.75 on the upside on Monday, eventually ending the session at $43.7, with a gain of 0.11% or 0.05 points. The heightened volatility saw the trading volume jump to 1,85,213 shares. Company has a market cap of $1,438 M.
On the company’s financial health, Natus Medical Inc reported $0.39 EPS for the quarter, beating the analyst consensus estimate by $ 0.05 according to the earnings call on Oct 19, 2016. Analyst had a consensus of $0.34. The company had revenue of $90.90 million for the quarter, compared to analysts expectations of $89.94 million. The company’s revenue was down -3.9 % compared to the same quarter last year.During the same quarter in the previous year, the company posted $0.39 EPS.
Many Wall Street Analysts have commented on Natus Medical Inc. The Benchmark Company Initiated Natus Medical Inc on Oct 4, 2016 to “Buy”, Price Target of the shares are set at $55.Natus Medical Inc was Upgraded by Raymond James to ” Outperform” on Sep 13, 2016.
Natus Medical Incorporated (Natus) is a provider of newborn care and neurology healthcare products and services used for the screening diagnosis detection treatment monitoring and tracking of common medical ailments in newborn care hearing impairment neurological dysfunction epilepsy sleep disorders and balance and mobility disorders. The Company offers two product families: Neurology which includes products and services for diagnostic electroencephalography and long term monitoring intensive care unit monitoring electromyography sleep analysis intra-operative monitoring and diagnostic and monitoring transcranial doppler ultrasound technology; and Newborn Care which includes products and services for newborn care including hearing screening brain injury thermoregulation jaundice management and various disposable products as well as products for diagnostic hearing assessment for children through adult populations and others.